CRISPR patent “case of the year” hearing is a must-watch – and not just for the life sciences 30 Apr 18
With news of the US Supreme Court’s recent Oil States decision and the UK’s ratification of the Unified Patent Court Agreement capturing the headlines in recent days, patent professionals might be forgiven for allowing a crucial CRISPR-Cas9 dispute to slip under the radar. But they would be wrong to do so.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
You have a great publication! It is the central professional journal in the field of intellectual assets.
Dr Lindsay Moore
CEO and president, KLM Inc Management Consultation
Adjunct Professor of Law, George Washington University Law School
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email